One exciting initiative that GPIT Futures is bringing to suppliers including DXS is by introducing GP Connect. The GP Connect programme will enable clinicians in different care settings, using solutions such as those which DXS offers, to communicate with one another providing complete interoperability with significant benefits to both patients and clinicians.
Having committed approximately £4 million of mainly internally generated funds into our new products and services during the past four years DXS is well positioned to generate considerable revenue growth from the
Although at an early stage, the Company’s three new Long-Term Condition Expert solutions, are all currently receiving positive responses from our pilot sites, where they are being thoroughly tested. These new solutions are designed to provide both users (clinicians) and healthcare funders (e.g.
Our strategic marketing campaign includes digital marketing and social media, conferences and is heavily weighted on referrals from satisfied customers.
The sales and marketing strategy in the
DXS Pointof Care, a best-of-breed Clinical Decision Support solution that includes automatic provision of decision support as part of clinician workflow and a comprehensive knowledge base and content rich pathways. In line with the NHSstrategy, we are in the process of building the new web-based solution which will ultimately replace the current version. This new solution is planned to offer users “smart templates” which will provide users with an increased return on their investment.
and the following new solutions to be launched shortly:
- CompleteCare, a complete, best evidence medicine clinical template toolset with analytics and reporting features designed to free-up time and maximise return in general practice;
- ExpertCare, a digital medicines optimisation solution designed to simplify complex medicines prescribing using expert algorithms that empowers nurses and pharmacists to manage complex hypertensive patients saving GP practices and the
NHSthousands of pounds per annum; and
- MyVytalCare, a comprehensive long-term condition management platform that digitally connects doctors and patients and improves condition control and treatment outcomes while saving practices time.
“The official launch of these new products and services is planned for early 2020. To ensure success the Company is in the process of reviewing its fundraising options to enable investment into sales, marketing and development.
In addition to the above, the Company is considering moving to AIM in the medium term. It is anticipated that this will facilitate additional funding for our planned international expansion.
Revenue streams, both locally and internationally, are anticipated to continue as a combination of recurring revenue from subscriptions from users and healthcare payers, as well as promotional revenue from the pharmaceutical industry who are seeking new innovative ways of reaching their markets.”
The Directors of
|City & Merchant ||020 7101 7676|
|020 3764 2341|
Note to Editors: